BRPI0410707A - composição que compreende antagonistas de receptores de progesterona e antiestrogênios puros para a profilaxia e tratamento de doenças dependentes de hormÈnios - Google Patents

composição que compreende antagonistas de receptores de progesterona e antiestrogênios puros para a profilaxia e tratamento de doenças dependentes de hormÈnios

Info

Publication number
BRPI0410707A
BRPI0410707A BRPI0410707-1A BRPI0410707A BRPI0410707A BR PI0410707 A BRPI0410707 A BR PI0410707A BR PI0410707 A BRPI0410707 A BR PI0410707A BR PI0410707 A BRPI0410707 A BR PI0410707A
Authority
BR
Brazil
Prior art keywords
dependent diseases
hormone dependent
treatment
composition
antiestrogens
Prior art date
Application number
BRPI0410707-1A
Other languages
English (en)
Inventor
Ulrike Fuhrmann
Jens Hoffmann
Martin Schneider
Gerhard Siemeister
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33450989&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0410707(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of BRPI0410707A publication Critical patent/BRPI0410707A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"COMPOSIçãO QUE COMPREENDE ANTAGONISTAS DE RECEPTORES DE PROGESTERONA E ANTIESTROGêNIOS PUROS PARA A PROFILAXIA E TRATAMENTO DE DOENçAS DEPENDENTES DE HORMÈNIOS". A presente invenção refere-se a métodos e usos para prevenir ou tratar doenças dependentes de hormónios, particularmente câncer de mama, em um mamífero, por uma combinação de uma antiprogestina, particularmente a antiprogestina 11<225>-(4-acetilfenil)-17b-hidróxi-17a-(1,1,2,2,2-pentafluoretil)-estr a-4,9-dien-3-ona ou um derivado ou análogo farmaceuticamente aceitável da mesma, e um antiestrogênio puro, particularmente um composto da fórmula geral (I), como definido no relatório descritivo, como por exemplo, 11b-flúor-17a-metil-7a-{5-¢metil-(8,8,9,9,9-pentafluomonil)-amino!-pe ntil}-estra-1,3,5(10)-trieno-3,17b-diol. A invenção refere-se ainda a composições farmacêuticas que compreendem a dita combinação.
BRPI0410707-1A 2003-05-28 2004-05-27 composição que compreende antagonistas de receptores de progesterona e antiestrogênios puros para a profilaxia e tratamento de doenças dependentes de hormÈnios BRPI0410707A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/446,165 US20040242551A1 (en) 2003-05-28 2003-05-28 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
PCT/EP2004/005732 WO2004105768A1 (en) 2003-05-28 2004-05-27 Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Publications (1)

Publication Number Publication Date
BRPI0410707A true BRPI0410707A (pt) 2006-06-13

Family

ID=33450989

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0410707-1A BRPI0410707A (pt) 2003-05-28 2004-05-27 composição que compreende antagonistas de receptores de progesterona e antiestrogênios puros para a profilaxia e tratamento de doenças dependentes de hormÈnios

Country Status (18)

Country Link
US (3) US20040242551A1 (pt)
EP (2) EP1834644A3 (pt)
JP (1) JP2006528226A (pt)
KR (1) KR20060005412A (pt)
CN (1) CN1893955A (pt)
AR (1) AR044450A1 (pt)
AU (1) AU2004243500A1 (pt)
BR (1) BRPI0410707A (pt)
CA (1) CA2524750A1 (pt)
CL (1) CL2004001317A1 (pt)
EA (1) EA011506B1 (pt)
MX (1) MXPA05012841A (pt)
NO (1) NO20056153L (pt)
PE (1) PE20050207A1 (pt)
TW (1) TW200505936A (pt)
UY (1) UY28334A1 (pt)
WO (1) WO2004105768A1 (pt)
ZA (1) ZA200510449B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10159217A1 (de) * 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases
JPWO2004111024A1 (ja) * 2003-06-10 2006-07-20 協和醗酵工業株式会社 チアジアゾリン誘導体
US20080268041A1 (en) * 2007-04-23 2008-10-30 Jens Hoffmann Combination of progesterone-receptor antagonist together with none-steroidal antiestrogen for use in brca mediated diseases
US20080261929A1 (en) * 2007-04-23 2008-10-23 Jens Hoffmann Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in brca mediated diseases
CA2683809A1 (en) * 2007-04-23 2008-10-30 Bayer Schering Pharma Aktiengesellschaft Progesterone-receptor antagonist for use in brca alone or as combination with antiestrogen
ES2708351T3 (es) * 2013-04-11 2019-04-09 Bayer Pharma AG Forma de dosificación de un antagonista del receptor de progesterona
CN115505019B (zh) * 2022-11-07 2024-01-26 南宁师范大学 7-酰胺取代雌甾类化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA931944A (en) * 1970-04-24 1973-08-14 Anner Georg Oestrogenically highly active steroids and process for their manufacture
US4666885A (en) * 1985-02-08 1987-05-19 Fernand Labrie Combination therapy for treatment of female breast cancer
EP0310542B1 (de) * 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE3733478A1 (de) * 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
DE19622457A1 (de) * 1996-05-24 1997-11-27 Schering Ag 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US5866560A (en) * 1996-08-20 1999-02-02 Schering Ag 7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
DE19706061A1 (de) * 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
AR015500A1 (es) * 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
DE19807791A1 (de) * 1998-02-19 1999-08-26 Schering Ag Kombinationspräparat aus Östrogen und Antiöstrogen
EE200300157A (et) * 2000-10-18 2003-08-15 Schering Aktiengesellschaft Antiprogestiinide kasutamine apoptoosi esilekutsumiseks rakus
ATE310522T1 (de) * 2000-10-18 2005-12-15 Schering Ag Verwendung von antiprogestinen zur prophylaxe und behandlung von hormonabhängigen erkrankungen
DE10159217A1 (de) * 2001-11-27 2003-06-05 Schering Ag 17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
US20040242551A1 (en) * 2003-05-28 2004-12-02 Schering Ag Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases

Also Published As

Publication number Publication date
WO2004105768A1 (en) 2004-12-09
US20040242551A1 (en) 2004-12-02
CL2004001317A1 (es) 2005-05-06
AR044450A1 (es) 2005-09-14
EA200501739A1 (ru) 2006-06-30
EA011506B1 (ru) 2009-04-28
EP1628669A1 (en) 2006-03-01
CA2524750A1 (en) 2004-12-09
US20050014736A1 (en) 2005-01-20
ZA200510449B (en) 2007-04-25
PE20050207A1 (es) 2005-04-28
KR20060005412A (ko) 2006-01-17
TW200505936A (en) 2005-02-16
JP2006528226A (ja) 2006-12-14
MXPA05012841A (es) 2006-02-13
UY28334A1 (es) 2004-12-31
CN1893955A (zh) 2007-01-10
NO20056153L (no) 2006-02-22
WO2004105768A8 (en) 2006-04-06
AU2004243500A1 (en) 2004-12-09
US20070238714A1 (en) 2007-10-11
EP1834644A3 (en) 2007-11-07
EP1834644A2 (en) 2007-09-19

Similar Documents

Publication Publication Date Title
BR0308784A (pt) Miméticos de glucocorticóides, métodos para fabricar os mesmos, composições farmacêuticas e usos dos mesmos
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
BR0312095A (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0410306A (pt) métodos para tratar, controlar ou evitar um cáncer especìfico, para tratar, controlar ou evitar uma doença associada com angiogênese indesejada e para reduzir ou evitar um efeito adverso, composição farmacêutica, e, kit
BRPI0516243C1 (pt) uso de um precursor de esteróide sexual selecionado do grupo que consiste em dehidroepiandrosterona, sulfato de dehidroepiandrosterona, androst-5-eno-3b,17b-diol e 4-androsten-3,17-diona, uso do referido precursor em 5 associação com um modulador de receptor de estrogênio seletivo para proteção uterina e da glândula mamária contra câncer, composição farmacêutica e kit
MX2007008614A (es) Peptidos con actividad agonista del receptor del neuropeptido-2 (y2r).
BRPI0416700A (pt) métodos para tratar obesidade, para alcançar perda de peso desejável, para evitar ganho de peso indesejável, e para facilitar a perda de peso em um indivìduo não sofrendo de depressão, métodos de manutenção de um peso estável e de redução do peso corporal em um indivìduo, composição farmacêutica, e, kit
EA201000157A1 (ru) Неосновные антагонисты рецептора меланин-концентрирующего гормона 1 типа и их применение
IL216194A0 (en) Pharmaceutical compositions of a neuroactive steroid and uses thereof
PL1735278T3 (pl) Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne
BRPI0507544A (pt) combinação de agonistas de benzotiazol-2-ona beta-2 adrenoreceptores e corticosteróides para o tratamento de doenças respiratórias
BR0114665A (pt) Uso de antiprogestinas para a profilaxia e tratamento de doenças dependentes de hormÈnio
BRPI0417161A (pt) compostos, composições farmacêuticas, e, uso de um composto
BRPI0410707A (pt) composição que compreende antagonistas de receptores de progesterona e antiestrogênios puros para a profilaxia e tratamento de doenças dependentes de hormÈnios
BRPI0413013A (pt) composto, seus sais, solvatos, e derivados farmaceuticamente funcionais, composição farmacêutica, uso de um composto, e, métodos para o tratamento ou profilaxia de condições ou distúrbios, e de doenças
BR9912816A (pt) Composição terapêutica à base de flavonóides, tencionada para uso no tratamento de tumores por agentes citotóxicos
BR0318242A (pt) derivados de azabiciclo hexano substituìdo como antagonistas de receptores muscarìnicos e processo para sua preparação
BR112022014933A2 (pt) Compostos e composições para uso no tratamento de distúrbios de pele
EA201000097A1 (ru) 8-бета-замещенные эстратриены в качестве селективно активных эстрогенов
BR0308517A (pt) Combinação de um antagonista do receptor de aldosterona e de um agente sequestrante de ácido biliar
BRPI0413670A (pt) composição farmacêutica para o tratamento de obesidade ou para facilitar ou promover a perda de peso
AR066231A1 (es) Combinacion de antagonista del receptor de progesterona con atiestrogenos no esteroidales para usar en enfermedades mediadas por brca (genes supresores de tumores)
TH76790A (th) สารผสมซึ่งประกอบรวมด้วยโปรเจสเทอโรน-รีเซพเตอร์ แอนทาโกนิสท์ และแอนติเอสโทรเจ็นบริสุทธิ์ สำหรับการป้องกันโรค และการบำบัดโรคที่ต้องพึ่งพาฮอร์โมน
TH76790B (th) สารผสมซึ่งประกอบรวมด้วยโปรเจสเทอโรน-รีเซพเตอร์ แอนทาโกนิสท์ และแอนติเอสโทรเจ็นบริสุทธิ์ สำหรับการป้องกันโรค และการบำบัดโรคที่ต้องพึ่งพาฮอร์โมน

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CONFORME ARTIGO 10O DA RESOLUCAO 124/06, CABE SER ARQUIVADO REFERENTE AO NAO RECOLHIMENTO DA 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.